ZMK (29)5 2013, S. 280–289

Dr. Raluca Cosgarea, Prof. Dr. Nicole Arweiler, Prof. Dr. Anton Sculean

Klinische Konzepte und neue Entwicklungen in der regenerativen Parodontalchirurgie

[1] Caton JG, Greenstein GG: Factors related to periodontal regeneration. Periodontol 2000 3 (1), 9–15 (1993).
[2] Cortellini P, Tonetti MS: Long-term tooth survival following regenerative treatment of intrabony defects. J Periodontol 75, 672–678 (2004).
[3] Cortellini P, Pini Prato G, Tonetti MS: Periodontal regeneration of human intrabony defects with bioresorbable membranes. A controlled clinical trial. J Periodontol 67, 217–223 (1996).
[4] Cortellini P, Paolo G, Prato P, Tonetti MS: Long-term stability of clinical attachment following guided tissue regeneration and conventional therapy. J Clin Periodontol 23, 106–111 (1996).
[5] Cortellini P, Pini-Prato G, Tonetti M: Periodontal regeneration of human infrabony defects (V). Effect of oral hygiene on long-term stability. J Clin Periodontol 21, 606–610 (1994).
[6] Cortellini P, Prato GP, Tonetti MS: The modified papilla preservation technique. A new surgical approach for interproximal regenerative procedures. J Periodontol 66, 261–266 (1995).
[7] Cortellini P, Prato GP, Tonetti MS: The simplified papilla preservation flap. A novel surgical approach for the management of soft tissues in regenerative procedures. Int J Periodontics Restorative Dent 19, 589–599 (1999).
[8] Cortellini P, Tonetti MS: Clinical performance of a regenerative strategy for intrabony defects: scientific evidence and clinical experience. J Periodontol 76, 341–350 (2005).
[9] Döri F, Arweiler N, Gera I, Sculean A: Clinical evaluation of an enamel matrix protein derivative combined with either a natural bone mineral or beta-tricalcium phosphate. J Periodontol 76, 2236–2243 (2005).
[10] Döri F, Arweiler N, Szantó E, Agics A, Gera I, Sculean A: Ten year results following treatment of intrabony defects with an enamel matrix protein derivative combined with either a natural bone mineral or a beta-tricalcium phosphate. J Periodontol 2012 [Epub ahead of print].
[11] Dori F, Huszar T, Nikolidakis D, Arweiler NB, Gera I, Sculean A: Effect of platelet-rich plasma on the healing of intrabony defects treated with an anorganic bovine bone mineral and expanded polytetrafluoroethylene membranes. J Periodontol 78, 983–990 (2007).
[12] Dori F, Huszar T, Nikolidakis D, Arweiler NB, Gera I, Sculean A: Effect of platelet-rich plasma on the healing of intra-bony defects treated with a natural bone mineral and a collagen membrane. J Clin Periodontol 34, 254–261 (2007).
[13] Dori F, Huszar T, Nikolidakis D, Tihanyi D, Horvath A, Arweiler NB, et al. Effect of platelet rich plasma on the healing of intrabony defects treated with a β-tricalcium phosphate and expanded polytetrafluoroethylene membranes. J Periodontol 79, 660–669 (2008).
[14] Dori F, Kovacs V, Arweiler NB, Huszar T, Gera I, Nikolidakis D, Sculean A: Effect of platelet-rich plasma on the healing of intrabony defects treated with an anorganic bovine bone mineral: a pilot study. J Periodontol 80, 1599–1605 (2009).
[15] Eickholz P, Horr T, Klein F, Hassfeld S, Kim T:. Radiographic parameters for prognosis of periodontal healing of infrabony defects: two different definitions of defect depth. J Periodontol 75, 399–407 (2004).
[16] Filippi A, Pohl Y, von Arx T: Treatment of replacement resorption with Emdogain – a prospective clinical study. Dent Traumatol 18, 138–143 (2002).
[17] Froum S, Lemler J, Horowitz R, Davidson B: The use of enamel matrix derivative in the treatment of periodontal osseous defects: a clinical decision tree based on biologic principles of regeneration. Int J Periodontics Restorative Dent 21, 437–449 (2001).
[18] Giannobile WV, Sommerman MJ: Growth and amelogenin-like factors in periodontal wound healing. A systematic review. Ann Periodontol 8, 193–204 (2003).

[19] Gottlow J, Nyman S, Lindhe J, Karring T, Wennström J: New attachment formation in the human periodontium by guided tissue regeneration. Case reports. J Clin Periodontol 13, 604–616 (1986).
[20] Guida L, Annunziata M, Belardo S, Farina R, Scabbia A, Trombelli L: Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects. J Periodontol 78, 231–238 (2007).
[21] Gurinsky BS, Mills MP, Mellonig JT: Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. J Periodontol 75, 1309–1318 (2004).
[22] Hammarström L: Enamel matrix, cementum development and regeneration. J Clin Periodontol 24, 658–668 (1997).
[23] Hanna R, Trejo PM, Weltman RL: Treatment of intrabony defects with bovine-derived xenograft alone and in combination with platelet-rich plasma: a randomized clinical trial. J Periodontol 75, 1668–1677 (2004).
[24] Haney JM, Nilvéus RE, McMillan PJ, Wikesjö UME: Periodontal repair in dogs: expanded polytetrafluoroethylene barrier membranes support wound stabilization and enhance bone regeneration. J Periodontol 64, 883–890 (1993).
[25] Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE: A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontol 68, 1186–1193 (1997).
[26] Jepsen S, Eberhard J, Herrera D, Needleman I: A systematic review of guided tissue regeneration for periodontal furcation defects. What is the effect of guided tissue regeneration compared with surgical debridement in the treatment of furcation defects? J Clin Periodontol 29 (Suppl 3), 103–116; discussion 160–102 (2002).
[27] Jepsen S, Heinz B, Jepsen K: A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. J Periodontol 75, 1150–1160 (2004).
[28] Karring T, Nyman S, Gottlow J, Laurell L: Development of the biological concept of guided tissue regeneration – animal and human studies. Periodontol 2000 1, 26–35 (1993).
[29] Karring T, Nyman S, Lindhe J: Healing following implantation of periodontitis affected roots into bone tissue. J Clin Periodontol 7, 96–105 (1980).
[30] Klein F, Kim TS, Hassfeld S: Radiographic defect depth and width for prognosis and description of periodontal healing of infrabony defects. J Periodontol 72, 1639–1646 (2001).
[31] Kwok V, Caton J: Prognosis revisited: a system for assigning periodontal prognosis. J Periodontol 78, 2063–2071 (2007).
[32] Lang NP, Tonetti MS: Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. J Clin Periodontol 23, 240–250 (1996).
[33] Lekovic V, Camargo PM, Weinlaender M, Nedic M, Aleksic Z, Kenney BE: A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. J Periodontol 71, 1695–1701 (2000).
[34] Lindhe J, Westfelt E, Nyman S, Sokransky SS, Haffajee AD: Long-term effect of surgical/non-surgical treatment of periodontal disease. J Clin Periodontol 11, 448–458 (1984).
[35] Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR: Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85, 638–646 (1998).
[36] Marx RE: Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 62, 489–496 (2004).
[37] Matuliene G, Pjetursson BE, Salvi GE, Schmidlin K, Brägger U, Zwahlen M, Lang NP: Influence of residual pockets on progression of periodontitis and tooth loss: results after 11 years of maintenance. J Clin Periodontol 35, 685–695 (2008).
[38] McGuire MK, Nunn ME: Prognosis versus actual outcome. II. The effectiveness of clinical parameters in developing an accurate prognosis. J Periodontol 67, 658–665 (1996).

[39] McGuire MK, Nunn ME: Prognosis versus actual outcome. III. The effectiveness of clinical parameters in accurately predicting tooth survival. J Periodontol 67, 658–665 (1996).
[40] Nevins M, Giannobile WV, McGuire MK: Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol 76, 2205–2215 (2005).
[41] Nyman S, Karring T, Lindhe J, Planten S: Healing following implantation of periodontitis-affected roots into gingival connective tissue. J Clin Periodontol 7, 394–401 (1980).
[42] Paolantonio M: Combined regenerative technique in human intrabony defects by collagen membranes and anorganic bovine bone. A controlled clinical study. J Periodontol 73, 158–166 (2002).
[43] Piemontese M, Aspriello SD, Rubini C, Ferrante L, Procaccini M: Treatment of periodontal intrabony defects with demineralised freeze-dried bone allograft in combination with platelet-rich plasma: a comparative clinical trial. J Periodontol 79, 802–810 (2008).
[44] Polimeni G, Xiropaidis AV, Wikesjö UME: Biology and principles of periodontal wound healing/regeneration. Periodontol 2000 41, 30–47 (2006).
[45] Polimeni G, Koo KT, Qahash M, Xiropaidis AV, Albandar JM, Wikesjö UME: Prognostic factors for alveolar regeneration: effect of a space-providing biomaterial on guided tissue regeneration. J Clin Periodontol 31, 725–729 (2004).
[46] Pontoriero R, Lindhe J: Guided tissue regeneration in the treatment of degree II furcations in maxillary molars. J Clin Periodontol 22, 756–763 (1995).
[47] Pretzl B, Kim TS, Steinbrenner H, Dörfer C, Himmer K, Eickholz P: Guided tissue regeneration with bioabsorbable barriers. III. 10-year results in infrabony defects. J Clin Periodontol 36, 349–356 (2009).
[48] Sculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M: Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol 35, 817–824 (2008).
[49] Sculean A, Donos N, Windisch P, Gera I, Brecx M, Reich E: Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. J Periodont Res 34, 310–322 (1999).
[50] Sculean A, Alessandri R, Miron R, Salvi GE, Bosshardt DD: Enamel matrix proteins and periodontal wound healing and regeneration. Clin Adv Periodontics 1, 101–117 (2011).
[51] Sculean A, Auschill TM, Donos N, Brecx M, Arweiler NB: Effect of an enamel matrix protein derivative (Emdogain) on ex vivo dental plaque vitality. J Clin Periodontol 28, 1074–1078 (2001).
[52] Sculean A, Windisch P, Keglevich T, Fabi B, Lundgren E, Lyngstadaas PS: Presence of an enamel matrix protein derivative on human teeth following periodontal surgery. Clin Oral Investig 6, 183–187 (2002).
[53] Sculean A, Windisch P, Keglevich T, Chiantella GC, Gera I, Donos N: Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative combined with a bovine-derived xenograft. Int J Periodont Restor Dent 23, 47–55 (2003).
[54] Sculean A, Barbé G, Chiantella GC, Arweiler NB, Berakdar M, Brecx M: Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. J Periodontol 73, 401–408 (2002).
[55] Sculean A, Chiantella GC, Windisch P, Gera I, Reich E: Clinical evaluation of an enamel matrix protein derivative (Emdogain) combined with a bovine derived xenograft (Bio-Oss) for the treatment of intrabony periodontal defects in humans. Int J Periodont Restor Dent 22, 259–267 (2002).
[56] Sculean A, Pietruska M, Schwarz F, Willershausen B, Arweiler NB, Auschill TM: Healing of human intrabony defects following regenerative periodontal therapy with an enamel matrix protein derivative alone or combined with a bioactive glass. A controlled clinical study. J Clin Periodontol 32, 111–117 (2005).
[57] Sculean A, Windisch P, Keglevich T, Gera I: Clinical and histological evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. Int J Periodont Restor Dent 25, 139–147 (2005).

[58] Sculean A, Nikolidakis D, Schwarz F: Regeneration of periodontal tissues: combinations of barrier membranes and grafting materials – biological foundation and preclinical evidence. A systematic review. J Clin Periodontol 35 (Suppl. 8), 106–116 (2008).
[59] Sculean A, Berakdar M, Chiantella GC, Donos N, Arweiler NB, Brecx M: Healing of intrabony defects following treatment with a bovine-derived xenograft and collagen membrane: a controlled clinical study. J Clin Periodontol 30, 73–80 (2003).
[60] Sculean A, Chiantella GC, Windisch P, Arweiler NB, Brecx M, Gera I: Healing of intrabony defects following treatment with a composite bovine derived xenograft (Bio-Oss Collagen) in combination with a collagen membrane (Bio-Gide PERIO). J Clin Periodontol 32, 720–724 (2005).
[61] Sculean A, Windisch P, Chiantella GC: Human histologic evaluation of an intrabony defect treated with enamel matrix derivative, xenograft, and GTR. Int J Periodont Restor Dent 24, 326–333 (2004).
[62] Sculean A, Schwarz F, Chiantella GC, Donos N, Arweiler NB, Brecx M, Becker J: Five-year results of a prospective, randomized, controlled study evaluating treatment of intra-bony defects with a natural bone mineral and GTR. J Clin Periodontol 34, 72–77 (2007).
[63] Tonetti MS, Prato GP, Cortellini P: Factors affecting the healing response of intrabony defects following guided tissue regeneration and access flap surgery. J Clin Periodontol 23, 548–556 (1996).
[64] Tonetti MS, Cortellini P, Lang NP, Suvan JE, Adriaens P, Dubravec D: Clinical outcomes following treatment of human intrabony defects with GTR/bone replacement material or access flap alone: a multicenter randomized controlled clinical trial. J Clin Periodontol 31, 770–776 (2004).
[65] Tonetti MS, Pini-Prato G, Cortellini P: Periodontal regeneration of human intrabony defects. IV. Determinants of healing response. J Periodontol 64, 934–940 (1993).
[66] Tozum TF, Demiralp B: Platelet-rich plasma: a promising innovation in dentistry. J Can Dent Assoc 69, 664a–h (2003).
[67] Trombelli L, Lee MB, Promsudthi A, Guglielmoni PG, Wikesjö UME: Periodontal repair in dogs: histologic observations of guided tissue regeneration with a prostaglandin E1 analog/methacrylate composite. J Clin Periodontol 26, 381–387 (1999).
[68] Tsitoura E, Tucker R, Suvan J, Laurell L, Cortellini P, Tonetti M: Baseline radiographic defect angle of the intrabony defect as a prognostic indicator in regenerative periodontal surgery with enamel matrix derivative. J Clin Periodontol 31, 643–647 (2004).
[69] Velasquez-Plata D, Scheyer ET, Mellonig JT: Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. J Periodontol 73, 433–440 (2002).
[70] Wikesjö UME, Selvig K: Periodontal wound healing and regeneration. Periodontol 2000 19, 21–39 (1999).
[71] Wikesjö UM, Crigger M, Nilvéus R, Selvig KA: Early healing events at the dentin-connective tissue interface. Light and transmission electron microscopy observations. J Periodontol 62, 5–14 (1991).
[72] Yilmaz S, Cakar G, Yildirim B, Sculean A: Healing of two and three wall intrabony periodontal defects following treatment with an enamel matrix derivative combined with autogenous bone. J Clin Periodontol 37, 544–550 (2010).
[73] Zucchelli G, Amore C, Montebugnoli L, de Sanctis M: Enamel matrix proteins and bovine porous bone mineral in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol 74, 1725–1735 (2003).